Total patients | Centre A | Centre B | Centre C | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ACOR-1 (N = 120) | ACOR-2 (N = 120) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | |
Sex | ||||||||||||
Men | 86 (71.7%) | 85 (70.8%) | > 0.99 | 29 (72.5%) | 25 (62.5%) | 0.47 | 27 (67.5%) | 32 (80%) | 0.31 | 30 (75%) | 28 (70%) | 0.80 |
Women | 34 (28.3%) | 35 (29.2%) | 11 (27.5%) | 15 (37.5%) | 13 (32.5%) | 8 (20%) | 10 (25%) | 12 (30%) | ||||
Age (years) | ||||||||||||
< 60 | 28 (23.3%) | 42 (35%) | 0.13 | 13 (32.5%) | 12 (30%) | 0.59 | 9 (22.5%) | 15 (37.5%) | 0.45 | 6 (15%) | 15 (37.5%) | 0.15 |
60–69 | 42 (35%) | 37 (30.8%) | 11 (27.5%) | 13 (32.5%) | 16 (40%) | 12 (30%) | 15 (37.5%) | 12 (30%) | ||||
70–79 | 40 (33.3%) | 28 (23.3%) | 13 (32.5%) | 9 (22.5%) | 13 (32.5%) | 10 (25%) | 14 (35%) | 9 (22.5%) | ||||
≥ 80 | 10 (8.3%) | 13 (10.8%) | 3 (7.5%) | 6 (15%) | 2 (5%) | 3 (7.5%) | 5 (12.5%) | 4 (10%) | ||||
Histology | ||||||||||||
Invasive adenocarcinoma | 119 (99.2%) | 120 (100%) | > 0.99 | 40 (100%) | 40 (100%) | > 0.99 | 40 (100%) | 40 (100%) | > 0.99 | 39 (97.5%) | 40 (100%) | > 0.99 |
Squamous cell carcinoma | 1 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.5%) | 0 (0%) | ||||
Histological grade | ||||||||||||
Well differentiated | 43 (35.8%) | 51 (42.5%) | 0.37 | 9 (22.5%) | 3 (7.5%) | 0.01† | 17 (42.5%) | 18 (45%) | 0.60 | 17 (42.5%) | 30 (75%) | 0.015† |
Moderately differentiated | 20 (16.7%) | 25 (20.8%) | 3 (7.5%) | 14 (35%) | 7 (17.5%) | 9 (22.5%) | 10 (25%) | 2 (5%) | ||||
Poorly differentiated | 4 (3.3%) | 2 (1.7%) | 1 (2.5%) | 0 (0%) | 0 (0%) | 1 (2.5%) | 3 (7.5%) | 1 (2.5%) | ||||
NR | 53 (44.2%) | 42 (35%) | 27 (67.5%) | 23 (57.5%) | 16 (40%) | 12 (30%) | 10 (25%) | 7 (17.5%) | ||||
Distance from tumour to mesorectal fascia | ||||||||||||
≤ 1 mm | 29 (24.2%) | 43 (35.8%) | 0.001‡ | 9 (22.5%) | 13 (32.5%) | 0.24 | 14 (35%) | 14 (35%) | 0.07 | 6 (15%) | 16 (40%) | 0.01† |
> 1 mm | 45 (37.5%) | 56 (46.7%) | 14 (35%) | 17 (42.5%) | 19 (47.5%) | 25 (62.5%) | 12 (30%) | 14 (35%) | ||||
Not reported | 46 (38.3%) | 21 (17.5%) | 17 (42.5%) | 10 (25%) | 7 (17.5%) | 1 (2.5%) | 22 (55%) | 10 (25%) | ||||
Distance from tumour to anal verge | ||||||||||||
0–5 cm | 24 (29.3%) | 37 (35.9%) | 0.51 | 2 (22.2%) | 8 (32%) | 0.15 | 13 (33.3%) | 13 (33.3%) | > 0.99 | 9 (26.5%) | 16 (41%) | 0.42 |
> 5–10 cm | 41 (50%) | 43 (41.7%) | 7 (77.8%) | 11 (44%) | 15 (38.5%) | 15 (38.5%) | 19 (55.9%) | 17 (43.6%) | ||||
> 10 cm | 17 (20.7%) | 23 (22.3%) | 0 (0%) | 6 (24%) | 11 (28.2%) | 11 (28.2%) | 6 (17.6%) | 6 (15.4%) | ||||
Stage | ||||||||||||
I | 2 (1.7%) | 0 (0%) | 0.38 | 0 (0%) | 0 (0%) | 0.95 | 1 (2.5%) | 0 (0%) | 0.384 | 1 (2.5%) | 0 (0%) | 0.679 |
II | 14 (11.7%) | 10 (8.3%) | 7 (17.5%) | 6 (15%) | 4 (10%) | 1 (2.5%) | 3 (7.5%) | 3 (7.5%) | ||||
III | 94 (78.3%) | 97 (80.8%) | 30 (75%) | 31 (77.5%) | 31 (77.5%) | 34 (85%) | 33 (82.5%) | 32 (80%) | ||||
IV | 10 (8.3%) | 13 (10.8%) | 3 (7.5%) | 3 (7.5%) | 4 (10%) | 5 (12.5%) | 3 (7.5%) | 5 (12.5%) |